Changes in the contractile parameters of myosin measured so far do not explain the clinical hypercontractility caused by such mutations. We propose that hypercontractility is due to an increase in the number of myosin heads (S1) that are accessible for force production. In support of this hypothesis, we demonstrate myosin tail (S2)-dependent functional regulation of actin-activated human b-cardiac myosin ATPase. In addition, we show that both S2 and MyBP-C bind to S1 and that phosphorylation of either S1 or MyBP-C weakens these interactions. Importantly, the S1-S2 interaction is also weakened by four myosin HCM-causing mutations but not by two other mutations. To explain these experimental results, we propose a working structural model involving multiple interactions, including those with myosin's own S2 and MyBP-C, that hold myosin in a sequestered state.
a r t i c l e s
Myosin is the force-producing element of cardiac muscle, and the overall contractile motion of a cardiac sarcomere is generated by many regulated protein-protein interactions among various proteins including myosin, actin, tropomyosin, troponin complexes, MyBP-C, and titin. The myosin thick filament alone is a complex structure containing myosin, MyBP-C, titin, and other proteins. Important low-resolution structures have been determined by a number of investigators using both skeletal [1] [2] [3] [4] [5] [6] and cardiac muscle [7] [8] [9] isolated thick filaments. However, the complexity of this multiprotein assembly makes the locations of its various components difficult to determine. Constantly improving highresolution cryo-EM techniques [10] [11] [12] [13] hold great promise for generating better-defined thick-filament structures in the future 14 .
HCM is a cardiac muscle disorder and a leading cause of sudden death in people under age 35 (refs. 15,16) . Approximately half of all HCM patients have mutations in genes encoding cardiac sarcomeric proteins, predominantly human β-cardiac myosin (~40%) and MyBP-C (~40%) [17] [18] [19] [20] [21] [22] . A leading hypothesis for the cause of clinical hypercontractility in HCM is that these mutations increase one or more key parameters that determine the power output of the heart 23, 24 . Because power output is the product of force and velocity, the key parameters are the velocity of actin movement along an ensemble of motors and the ensemble force produced (F ensemble ), which can be estimated as: in which F intrinsic is the intrinsic force of a single myosin motor, N a is the number of myosin heads that are functionally accessible for interaction with actin in the sarcomere, and dr is the duty ratio or fraction of those accessible myosin heads strongly bound to actin at any point during contraction.
Most HCM-related mutations are found in S1 (or subfragment 1) of myosin. For two human β-cardiac S1 HCM mutations, D239N and H251N (early onset, pathologically severe), intrinsic force, velocity (as measured by in vitro motility assays), and ATPase activity are 30-90% higher than those in wild-type (WT) S1 (ref. 25) (Table 1) , thus easily accounting for clinically observed hypercontractility. However, human β-cardiac S1 HCM mutations that typically result in adultonset disease, such as R403Q 26 and R453C 27 , show less severe effects in vitro, as compared with previously described results in a mouse α-cardiac myosin model 23 , with the largest observed change being an ~50% increase in F intrinsic compared with that of WT 27 (Table 1) . Furthermore, these changes for any particular mutant occur in both directions, thus contributing to hypercontractility in some parameters and hypocontractility in others ( Table 1) .
One hotspot for HCM mutations in S1 is the converter domain 28 , which connects the catalytic domain of S1 to its light-chain-bound lever arm and is instrumental in converting the chemical energy of ATP hydrolysis to mechanical movement. Recent studies of three converter-domain mutations in human β-cardiac myosin that also typically result in adult-onset disease, R719W, R723G, and G741R, have indicated similar small changes in F intrinsic , velocity, and ATPase relative to those of WT myosin, with most changes being 20% or less in either hypercontractile or hypocontractile direction and with G741R showing no significant changes in these three parameters 29 (Table 1) . Therefore, for all five of these typically adult-onset HCM mutant myosin proteins examined, the changes in these fundamental parameters were 50% or less, and some contributed to hypercontractility, whereas others contributed to hypocontractility, thus making it difficult to determine the net change in contractility.
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VOLUME 24 NUMBER 6 JUNE 2017 nature structural & molecular biology a r t i c l e s One often-ignored parameter in the F ensemble equation is N a , the number of myosin heads functionally accessible for interaction with actin. This parameter may be key in fine-tuned regulation of the heart [30] [31] [32] [33] , and, as previously hypothesized 25, 28, 29, [34] [35] [36] [37] , may be pivotal in determining the hypercontractility known to arise from HCM mutations in human β-cardiac myosin.
We have previously observed that a relatively flat surface of the myosin motor domain, which we named the myosin mesa, is almost completely conserved in all cardiac species from mouse α-cardiac myosin to human β-cardiac myosin 36 . The myosin mesa is yet another hotspot for myosin HCM mutations 28, 36 ; ~70% of the variants in the human population that map to this region produce disease 28 , and many of these mutations alter arginine residues 36 . We have proposed that the cluster of arginine residues on the mesa that are mutated in HCM are likely to act as a binding domain for another protein, thereby holding the myosin heads in an inactive form 36 . We noted two candidate binding partners near S1 in the sarcomere 36, 37 : (i) the proximal 126 residues of the coiled-coil subfragment 2 (S2) tail region of myosin (proximal S2) and (ii) MyBP-C, which is in myosin thick filaments in a ratio of one MyBP-C to approximately six myosin molecules 38 . In comparison with cardiac myosin, most residues on the mesa are conserved in fast skeletal muscle, which has MyBP-C, whereas many mesa residues have been changed in smooth muscle myosin and nonmuscle myosin II, which lack MyBP-C 36 . This observation supports our hypothesis that MyBP-C might be a binding partner for the mesa region. Regarding possible proximal S2 binding to the mesa, outside of the myosin head domain, the one hotspot for HCM mutations is the proximal S2 region 19, 28 , where mutations primarily occur in glutamate and aspartate residues, which would be complementary to the arginine residue charges on the mesa.
Structural evidence for interaction of S1 with the proximal S2 tail from the same molecule has been observed for isolated heavy meromyosin (HMM, a soluble fragment of myosin consisting of two S1 heads attached to S2) [39] [40] [41] [42] , myosin molecules [40] [41] [42] [43] , and intact thick filaments [1] [2] [3] 7, 8 . The first 3D structure of a folded state of myosin, named the interacting heads motif (IHM), came from a cryo-EM study of unphosphorylated smooth muscle myosin 39 and describes a 2.0-nm-resolution map of an asymmetric interaction between the S1 domains. In this folded 'off state' of the motor domains, a binding surface of the 'blocked head' binds to the converter domain of the 'free head' . In the folded-back IHM structure, the blocked head may also be in structural contact with the proximal S2 (refs. 1, 2, 25, 40, 43, 44) . The IHM has also been observed in other classes of muscle myosin, including striated muscle myosins 41 , and in images of intact thick filaments isolated from a variety of muscle types [1] [2] [3] [4] [5] [6] . Thick-filament structures of 2.0-to 4.0-nm resolution have been obtained with cryo-EM for tarantula skeletal muscle 1,2 , Limulus telson muscle 3 , and vertebrate cardiac muscle 7, 8 . The solved crystal structure of human β-cardiac proximal S2 reveals possible charge interactions between the S2 and the S1 (ref. 34) , and these have been discussed as part of a general mechanism of shutting down S1 heads from interaction with actin 40, 41 . All of this evidence is consistent with the concept that N a is highly regulated in the heart.
Here we report functional ATPase data and binding data that support our mesa hypothesis. Importantly, we show effects of various HCM mutations on the affinity of the S1-S2 interactions that are consistent with a homology model of a human β-cardiac folded-back myosin structure that we built using a tarantula structural template. We present arguments suggesting that many, if not most, myosin HCM mutations effectively weaken interactions in this sequestered complex, thereby liberating more heads for subsequent interaction with actin during systolic contraction and resulting in hypercontractility of the heart.
RESULTS

Model of a sequestered complex of human b-cardiac myosin
On the basis of the folded-back sequestered heads previously described by low-resolution EM, we built a homology model for a folded-back, closed structure of human β-cardiac myosin 45 ( Fig. 1) , using the 3D-reconstructed structure of tarantula skeletal muscle thick filaments 2 . We emphasize that this homology model is not an actual structure of the folded-back state of human β-cardiac myosin, but it serves as a structural model to guide experiments. Inasmuch as similar foldedback structures have been described for other myosins [1] [2] [3] [4] [5] [6] [7] 9, 14, [39] [40] [41] 43 , including human cardiac myosin 8 , we found that our homology model provided a good working hypothesis for our studies.
The open and closed configurations of this structure are proposed to be in equilibrium (Fig. 1a) . One head is called the 'blocked head' (Fig. 1b, left) , because its actin-binding interface is not available for interaction with actin, and the second head is called the 'free head' 39 ( Fig. 1b, right) . When the structure is viewed from its back side (the side facing the shaft of the thick filament in the 3D reconstructions 2 ), the proximal S2 is cradled by the mesa domains of the S1 heads (Fig. 1b) . These regions contain a considerable number of pathogenic HCM mutations 28 . Several positively charged mesa residues (Fig. 1b, blue) are in proximity to a cluster of negatively charged residues on the proximal S2 that are mutated in HCM 28 (Fig. 1b, red) . This observation suggests a possible electrostatic interaction between the mesa and the proximal S2 that is important for sarcomere function. Notably, the S2 tail in this model is in closest contact with the mesa of the blocked head (Fig. 1b) .
Rotating this model 180° about its vertical axis to show the front side indicates a surface of the blocked head (Fig. 1c , dark-gray residues) that abuts the converter domain of the free head (Fig. 1c, white  residues) . The converter is another hotspot for HCM mutations 28 . Interestingly, there are virtually no HCM mutations on the surfaces of the S1 catalytic domains seen from this front view 28 . The region of the blocked-head surface (dark gray, bottom right of the molecule) that binds to the free-head converter surface is distinct from the actin-binding region (yellow), which in turn is distinct from the mesa surface, as we have defined it (pink) (Fig. 1d) . Interestingly, the R403Q mutation lies near the apex of the resulting pyramidal structure ( Fig. 1d and Supplementary Video 1) .
Actin-activated b-cardiac myosin ATPase regulation depends on the presence of proximal S2 Our mesa hypothesis 36, 37 states that interactions between S1 and proximal S2 and/or MyBP-C would sequester heads from being able to Table 1 Fundamental parameters of the actin-sS1 system with sS1 HCM mutants relative to wild-type sS1 a r t i c l e s interact with actin. To set up a functional assay, we took advantage of observations that phosphorylation of Ser15 on the myosin regulatory light chain (RLC) has considerable effects on cardiac muscle force production, shortening velocity and peak power output, and is altered during cardiac disease states [46] [47] [48] . To test our mesa hypothesis and explore the effects of RLC phosphorylation on the function of cardiac myosin, we created two constructs that resembled conventional heavy meromyosin (HMM) but with shortened S2 tails. The first was a GFP-tagged two-headed human β-cardiac myosin construct that lacked the S2 domain, except for the first two heptads (2-hep HMM, Fig. 2a) , and therefore presumably could not form a sequestered state with proximal S2 interacting with the S1 heads, which would inhibit the myosin ATPase. It dimerizes via a leucine zipper moiety 49 and was found to migrate as a dimer by native gel electrophoresis (data not shown). Moreover, it showed excellent activity in in vitro motility assays, propelling actin filaments at 1.5 µm s −1 at 23 °C, and showed an intrinsic force of 1.8 pN in laser-trap singlemolecule assays. The stoichiometry of the complex was 1:1:1 for HC/ essential light chain (ELC)/RLC. The second HMM-like construct was a 25-hep HMM version of human β-cardiac myosin, which had its proximal S2 as part of the same molecule as the myosin heads (Fig. 2b) .
In agreement with all heads being active in the phosphorylated state, the phosphorylated forms of 25-hep and 2-hep HMM showed The heavy-chain residues of the S1 head on the left (blocked head, outlined in black) are colored pink (mesa residues), dark blue (arginine HCM mutations), light blue (a histidine HCM mutation), white (the converter domain), and dark gray (all remaining residues). The ELC is colored light brown, and the RLC is light green. The heavy-chain residues of the S1 head on the right (free head) are colored dark pink (mesa residues), dark blue (arginine HCM mutations), light blue (a histidine HCM mutation), and light gray (all remaining residues). The ELC is colored dark brown, and the RLC is colored dark green. The proximal S2 tail is shown in teal, with glutamate and aspartate residues mutated in HCM in red. (c) The front-side view of the sequestered state showing the blocked head (outlined in black) interacting with the converter domain (white) of the free head (left). (d) The catalytic domain of human β-cardiac myosin forms a pyramidal structure (thick white solid lines). The three surfaces are the mesa (pink residues with arginine HCM mutations shown in dark blue), the actin-binding interface (yellow, according to the residues involved, as discussed [64] [65] [66] [67] , and the blocked-head surface (dark gray) that abuts the converter domain of the free head in the folded, sequestered-head state (marked by the red residue Asp382, whose mutation to tyrosine is an early-onset HCM mutation). These different interfaces are shown in different orientations of the myosin molecule in the red circles. Coordinates of the homology modeled folded-back human β-cardiac myosin are available for download (MS01, Supplementary Data Set 1). (Fig. 2a,b) . However, in the case of the 25-hep HMM, the nonphosphorylated form (1.4 ± 0.1 s −1 ) showed an ~40% decrease in k cat compared with its phosphorylated form (Fig. 2b) , in agreement with S1 heads being sequestered into a nonfunctional state dependent on the presence of proximal S2. This conclusion was supported by the finding that no such decrease in k cat was observed with nonphosphorylated 2-hep HMM (2.5 ± 0.1 s −1 ), for which there was no proximal S2 with which the S1 heads could interact (Fig. 2a) .
Human b-cardiac short S1 binds to the proximal part of human cardiac S2
We next sought biochemical evidence that proximal S2 binds to the myosin head in the absence of RLC phosphorylation. Our first experiments involved short S1 (sS1), a truncated form of S1 lacking the RLC and its heavy-chain-binding domain. We investigated interactions between sS1 and proximal S2 by using microscale thermophoresis (MST), a technique that follows the diffusion of a fluorescent probe along a temperature gradient and can be used to measure bimolecular interactions over a broad range of affinities, including a K d in the double-digit micromolar range [50] [51] [52] . We first validated that MST was able to measure the affinities of four known protein-protein interactions involving sS1, actin, proximal S2, and MyBP-C (Fig. 3a) . We then used sS1 fluorescently tagged with a C-terminal GFP to measure binding to proximal S2 (Fig. 3b) . A control with GFP alone showed no binding to S2. In contrast, we observed binding between sS1 and proximal S2 with a K d of 4 ± 1 µM in 25 mM KCl and a K d of 46 ± 7 µM (P < 0.05) in 100 mM KCl, thus indicating an electrostatic interaction between the sS1 and proximal S2. Similar results were observed with sS1 fluorescently tagged with Cy5-labeled cysteine residues (Supplementary Fig. 1 , K d of 1.5 ± 0.5 µM at 25 mM KCl and 34 ± 4 µM at 100 mM KCl). Notably, because the S1 and S2 domains are physically connected to each another in the sarcomere, the effective concentrations of S1 and S2 were estimated to be ~60 µM (estimation in Supplementary Note), and thus a K d in the double-digit micromolar range may be physiologically relevant.
Next, we used MST binding assays to test whether the binding of 2-hep HMM to S2 was weakened by phosphorylation of its RLC (Fig. 3c) . Whereas the nonphosphorylated 2-hep HMM bound proximal S2 with a K d of 8 ± 3 µM at 25 mM KCl, the phosphorylated 2-hep HMM bound with a much lower affinity (K d = 65 ± 5 µM; P < 0.05 by two-sided unpaired Student's t test) (Fig. 3c) . At 100 mM KCl, the K d for nonphosphorylated 2-hep HMM was 20 ± 3 µM, whereas the phosphorylated 2-hep HMM again bound with a much lower affinity (K d >60 µM) (Supplementary Fig. 2 ).
HCM mutations decrease the affinity of sS1-S2 binding
If the myosin mesa interacts with proximal S2, thereby sequestering myosin heads, we hypothesized that the S1 mesa arginine and lysine residues and the proximal S2 glutamate and aspartate residues that give rise to HCM when mutated would shift the equilibrium of the a r t i c l e s S1-S2 interaction to a more open state, thereby increasing the number of functionally accessible heads and causing hypercontractility of the sarcomere, in agreement with clinical observations. To this end, we investigated the binding of sS1with HCM-causing mutations (R453C or R249Q) to proximal S2, because these mutations in the blocked head lie near the proposed position of proximal S2 binding in the sequestered-complex model ( Fig. 4a and Supplementary Video 2) . Both R453C sS1 and R249Q sS1 binding to proximal S2 was much weaker (K d >90 µM for R453C and K d >300 µM for R249Q) than WT sS1 binding (K d of 46 ± 7 µM) (Fig. 4b) . In a separate study 25 , the early-onset HCM mutation H251N, which is next to R453C and R249Q in the myosin mesa in our working model (Fig. 4a) , has also been found to substantially weaken the binding of sS1 to S2 (green curve in Fig. 4b ; data from Adhikari et al. 25 ). Controls for the observed effects on sS1-S2 binding were the examination of HCM mutations that are not structurally adjacent to S2 in our model. For example, R403Q, which is on the far outer edge of the blocked-head mesa and is buried in the interaction between the two heads ( Fig. 4a) , was not predicted to affect the sS1-S2 interaction. The R403Q sS1 showed an affinity for S2 (K d of 54 ± 4 µM) similar to that of WT sS1 (K d of 46 ± 7 µM) (Fig. 4b) . Similarly, D239N in sS1, on the other side of the molecule from the mesa, has no effect on the affinity of sS1 for proximal S2 compared with WT sS1 (ref. 25) . However, these mutations may well affect other interactions holding the complex together.
To further test our hypothesis, we examined the aspartate and glutamate HCM mutations in the proximal S2 domain that are near the mesa to determine whether they would also weaken the binding of sS1 to S2. D906G S2, which overlies the blocked-head mesa, exhibited no binding to sS1 up to 250 µM proximal S2, in contrast to WT S2 (K d of 46 ± 7 µM) (Fig. 4c) . A control for the lack of binding of the D906G S2 was the proximal S2 HCM mutation R870H, which is outside the range of the mesa (Fig. 4a and Supplementary Video 1) . R870H S2 and WT S2 binding to sS1 showed similar affinities (K d of 59 ± 2 µM and 46 ± 7 µM, respectively) (Fig. 4c) .
b-cardiac sS1 binds MyBP-C, and binding is weakened by MyBP-C phosphorylation As discussed above, we hypothesized that the myosin mesa might serve as an interacting platform for MyBP-C 36 . Results showing binding of the C1-C2 fragment of MyBP-C to proximal S2 (ref. 53 ) and the proximity of proximal S2 to the myosin mesa (Figs. 1b and 4a) are consistent with this hypothesis.
We directly tested for binding of MyBP-C to sS1 by using MST. The human cardiac MyBP-C, homology modeled on the basis of known structures of some of the domains (Online Methods), is shown in Figure 5a . We found that full-length recombinant human nonphosphorylated MyBP-C bound sS1 (which does not contain the RLC that was previously shown to bind the C0 domain of MyBP-C 54 ) with a K d of 17 ± 2 µM (Fig. 5b) . Phosphorylation of the MyBP-C with protein kinase A (PKA) significantly decreased the binding affinity (K d of 37 ± 2 µM, P < 0.05, by two-sided unpaired Student's t test) (Fig. 5b) . Similar but somewhat weaker binding (K d of 33 ± 2 µM, P < 0.05) was seen with nonphosphorylated C0-C2 (Fig. 5c) . As for the full-length MyBP-C, binding was weaker after phosphorylation of C0-C2 with PKA (K d of 63 ± 3 µM, P < 0.05) (Fig. 5c) .
All converter HCM mutations lie near the interface of the two folded-back S1 heads
In addition to the biochemical interactions demonstrated here and previously 53, 54 , there is a predicted S1-S1 interaction that involves various associations, most prominently between a blocked-head surface adjacent to the mesa (Fig. 1d) and the converter domain of the free head (Fig. 6a,b) . The converter domain is of great interest in HCM because it is the hottest spot for HCM mutations, for which all reported variants to date in humans have proven to be HCM-causing pathogenic mutations 28 . We therefore modeled the converter HCM mutations into the homology-modeled folded-back human β-cardiac myosin shown in Figure 1 . Strikingly, all nine of the converter-domain mutations examined are positioned near the interface of the free-head converter and the blocked-head binding face (Fig. 6b-e) . Furthermore, R719W on the converter (Fig. 6d,e , middle cyan residue) of the free head is potentially in direct contact with the severe early-onset HCM-mutant residue D382Y 55, 56 on the binding face of the blocked head (Fig. 6e, red  residue) . This possible proximity, however, must be confirmed in an actual high-resolution structure of the folded state of human β-cardiac HMM. Additionally, this view of Arg453 on the mesa and Glu875 on S2 shows their proximity in our working model.
Examination of the binding interface with the vacuum electrostatics mode in PyMOL suggested an electrostatic interaction in which the binding interface of the converter domain of the free head is generally positively charged (Fig. 6f) , Arg723 and Arg719 are key a r t i c l e s residues, and the binding interface of the blocked-head domain is generally negatively charged (Fig. 6g) . Beyond weakening a general charge-charge interaction between the blocked and free head, any one of these converter HCM mutations is likely to perturb the structure of the domain in which it resides, and such a structural change may weaken the interaction between the two domains. The same can be said for HCM mutations in other regions of the molecule that may be involved in the proposed interactions holding the complex in a closed, sequestered state.
DISCUSSION
Notably, the resolution of all available IHM models is only ~2 nm, and resolutions better than 3 Å are necessary to determine how side chains are oriented and how they may affect myosin function 12, 13 . It is not possible to know how the high-resolution information of the myosin heads changes after they fold back into the IHM state. Furthermore, because ~40% of the residues of the S1 domains differ between human β-cardiac myosin and tarantula skeletal myosin, the actual human β-cardiac folded structure will be different in highresolution detail. Thus, these models and our homology model of human β-cardiac myosin can serve only as a guide and should not be treated as actual high-resolution structures. High-resolution EM reconstruction images or X-ray crystallography structures with purified human β-cardiac HMM will therefore be necessary to begin to assess the more detailed aspects of the effects of HCM mutations. Inferences such as specific side chain interactions, must be delayed until after these true structures become available.
Similar caution should be taken regarding the relationship between the folded-back sequestered state and the very interesting superrelaxed state (SRX) of myosin molecules described in both skeletal and cardiac fiber studies 31, 32, 57 . SRX is defined as a subpopulation of myosin molecules in the sarcomere that release nucleotides from the myosin active site extremely slowly (half-life of ~100 s) 31, 32, 57 . Although the molecular nature of this state has not been identified, the folded-back sequestered state observed through EM has been ascribed to the SRX state 5, 58 . This relationship seems highly likely, but the role of thick-filament proteins such as MyBP-C or titin in decreasing basal-level ATPase rates to the SRX level needs to be explored. There are data for purified dephosphorylated smooth muscle HMM indicating a very slow ATPase activity (<0.004 s −1 ) 59 , but phosphorylation/dephosphorylation is an on/off switch for smooth muscle, unlike striated muscle. To understand the role of SRX in HCM, it is therefore very important to biochemically demonstrate a r t i c l e s with purified β-cardiac myosin (or HMM) whether dephosphorylated myosin alone results in a decrease in basal ATPase relative to the levels in the SRX in fibers. If not, then which proteins must be added (MyBP-C, titin, and others) to myosin to decrease the ATPase activity to the low SRX values?
The binding of MyBP-C to sS1 (Fig. 5) places little constraint on where the binding occurs. However, C0 binds to the myosin RLC 54 , and C1-C2 binds to proximal S2 (ref. 53) . One model consistent with these results is shown in Figure 7a . The model can also account for the observation that the R870H S2 HCM mutation decreases the binding affinity of this domain for the C1-C2 domain of MyBP-C by over an order of magnitude 53 (Figs. 4a and 7a) . The model shown in Figure 7b is consistent with our observation that the binding of C0-C2 to sS1 was two-fold weaker than that of full-length MyBP-C (Fig. 5) . This result was consistent in duplicate experiments from different protein preparations and may suggest that the C4-C10 domains play a role in sequestered-complex formation. These models may be used to direct future experimental work to test their validity.
We propose that the sequestered state is held together by a series of relatively weak interactions between the two S1 heads; S1 and proximal S2; MyBP-C and S1; and MyBP-C and S2. Additional interactions in the sarcomere may be between the myosin head of one molecule and that of its neighboring molecule in the helical array of the thick filament 1, 5, 8 ; between the folded heads and the light meromyosin (LMM) backbone; and possibly between myosin and titin. Arg403 is in a position to potentially interact with MyBP-C, actin, the converter, or near the converter of the free head (Fig. 1d) . The R403Q mutation has very little effect on actin interaction 26 , so we propose that it may be involved in either weakening the C0-C2 interaction with the mesa or the blocked-head interaction with the free head. Similarly, the D382Y mutation (Fig. 1d) was predicted to interrupt the S1-S1 interaction. Future experiments will be directed at testing these predictions.
The decreases in K d that we observed for sS1 binding to proximal S2 when comparing R453C and R249Q human β-cardiac sS1 and WT sS1 were nearly an order of magnitude, a decrease that on its own would be predicted to release a substantial fraction of heads in the sequestered complex for interaction with actin (Supplementary Note). If a substantial portion of the myosin heads were in the sequestered state under normal conditions of heart function, such a large change might not be well tolerated. Our hypothesis, however, is that beyond the sS1-S2 interaction, the sequestered complex is held together by a number of other associations, as described above. Thus, an orderof-magnitude decrease or increase in binding affinity of any one of these interactions would lead to a smaller change in the fraction of heads released than would be expected if there were only one type of intra-or intermolecular interaction.
In summary, it is becoming increasingly clear that many myosin heads in the sarcomere are in a sequestered state, held in equilibrium with actively cycling heads (Fig. 8) . This equilibrium is shifted toward more active heads by phosphorylation of the myosin RLC and the M domain of MyBP-C, thus providing fine-tuned control of cardiac function by adrenergic stimulation. In the cardiac sarcomere, we additionally hypothesize that the open-to-closed myosin equilibrium is shifted toward open active heads by a large number of myosin HCM mutations, thereby causing hypercontractility of the heart. Notably, none of the HCM mutations studied here strengthen the sS1-S2 interactions, but they weaken binding, in accordance with our hypothesis and structural model. A majority of MyBP-C HCM mutations are truncations, which may lead to loss of the protein and to haploinsufficiency [60] [61] [62] . The considerations described here may suggest that the MyBP-C HCM truncation mutations simply decrease the level of the tightly bound state involving MyBP-C (Fig. 8) 
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Other than the interactions shown here, many other interactions, for example those involving the LMM and titin, are probably involved in the sequestered state of myosin, and a common theme for HCM mutations may be that they shift the equilibrium away from the sequestered foldedback state of the myosin heads to the open state, which is functionally accessible for interaction with actin, thus producing the hypercontractility observed clinically.
